BRIDGEBIO PHARMA INC.

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

06 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

04 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

03 6 2024 16:01:00 提供 Nasdaq GlobeNewswire

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

29 5 2024 16:01:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

24 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

14 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

13 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

02 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

02 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

10 4 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

07 4 2024 13:15:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

20 3 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

05 3 2024 23:53:56 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

04 3 2024 16:17:36 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

04 3 2024 02:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

22 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

07 2 2024 07:34:22 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 2 2024 07:30:00 提供 Nasdaq GlobeNewswire

BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

05 2 2024 07:30:00 提供 Nasdaq GlobeNewswire